





































































Natural History of Asymptomatic Severe Aortic Stenosis
and the Association of Early Intervention With Outcomes
A Systematic Review and Meta-Analysis
Brigitta Gahl, PhD; Mevlüt Çelik, MD; Stuart J. Head, MD, PhD; Jean-Louis Vanoverschelde, MD, PhD;
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A. Pieter Kappetein, MD, PhD; Peter Jüni, MD; Bruno R. da Costa, PhD
IMPORTANCE Whether intervention should be performed in patients with asymptomatic
severe aortic stenosis (AS) remains debated.
OBJECTIVE To meta-analyze the natural history of asymptomatic severe AS and examine the
association of early intervention with survival.
DATA SOURCES PubMed, Embase, and Cochrane databases were searched from inception to
February 1, 2020.
STUDY SELECTION Observational studies of adult patients with asymptomatic severe AS.
DATA EXTRACTION AND SYNTHESIS Two investigators independently extracted study and
patient characteristics, follow-up time, events, and prognostic indicators of events.
Random-effects models were used to derive pooled estimates.
MAIN OUTCOMES AND MEASURES The meta-analysis on natural history was performed on the
primary end point of all-cause death occurring during a conservative treatment period, with
secondary end points consisting of cardiac death, death due to heart failure, sudden death,
development of symptoms, development of an indication for aortic valve intervention, and
aortic valve intervention. The primary end point for the meta-analysis of early intervention vs
a conservative strategy was all-cause death during long-term follow-up. Finally, meta-analysis
was performed on the association of prognostic indicators with the composite of death or
aortic valve intervention found in multivariable models.
RESULTS A total of 29 studies with 4075 patients with 11 901 years of follow-up were
included. Pooled rates per 100 patients per year were 4.8 (95% CI, 3.6-6.4) for all-cause
death, 3.0 (95% CI, 2.2-4.1) for cardiac death, 2.0 (95% CI, 1.3-3.1) for death due to heart
failure, 1.1 (95% CI, 0.6-2.1) for sudden death, 18.1 (95% CI, 12.8-25.4) for an indication for
aortic valve intervention, 18.5 (95% CI, 13.4-25.5) for development of symptoms, and 19.2
(95% CI, 15.5-23.8) for aortic valve intervention. Early intervention was associated with a
significant reduction in long-term mortality (hazard ratio, 0.38; 95% CI, 0.25-0.58). Factors
associated with worse prognosis were severity of AS, low-flow AS, left ventricular damage,
and atherosclerotic risk factors.
CONCLUSIONS AND RELEVANCE Data from observational studies and a recent randomized
clinical trial suggest that many patients with asymptomatic severe AS develop an indication
for aortic valve intervention, and their deaths are mostly cardiac but not only sudden. Other
end points besides sudden death should be considered during the decision to perform early
intervention that are associated with improved survival.
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P atients with symptomatic severe aortic stenosis (AS)have an indication for surgical aortic valve replace-ment (SAVR) or transcatheter aortic valve replace-
ment. The role of intervention is less clear in patients with
asymptomatic severe AS. North American and European guide-
lines agree on a class I indication for SAVR in patients with a
reduced left ventricular (LV) ejection fraction (<50%) but are
inconsistent for patients with other disease or comorbid
factors.1-3
Studies suggest that as many as 50% of patients with
asymptomatic severe AS progress to a symptomatic status and
require surgery within the first 2 years of follow-up4 and that
this waiting period increases the risk of sudden cardiac death
and congestive heart failure.5,6 In light of these results, the con-
cept of early intervention has raised increasing interest.5,7 How-
ever, advocates of a conservative approach argue that the pro-
cedural risk does not balance against the potential benefits of
early intervention and that many patients will never become
symptomatic.8 Such arguments come mainly from single-
center observational studies with few patients and based on
events that occur infrequently.1
The natural history should be better quantified to improve
our understanding of potential benefits and harms of interven-
tion vs conservative treatment. Moreover, risk factors of poor
prognosis should be identified to evaluate which patients are
at highest risk and may particularly benefit from early inter-
vention. Therefore, we have performed a systematic review and
meta-analysis of studies evaluating the natural history of pa-
tients with asymptomatic severe AS and determined whether
early intervention improves long-term survival.
Methods
Search Strategy and Study Inclusion
The PubMed, Embase, and Cochrane databases were searched
from their inception to February 1, 2020, for full-length, Eng-
lish-language, observational studies that reported on pa-
tients with asymptomatic severe AS who were initially treated
conservatively. We searched among titles and abstracts using
the keywords asymptomatic AND aortic AND stenosis. No search
software was used. Authors were not contacted for studies that
did not fulfill inclusion criteria or if data were unclear. This
study complies with the Meta-analysis of Observational Stud-
ies in Epidemiology (MOOSE) reporting guideline.9
Two investigators (S.J.H. and M.Ç.) independently re-
viewed the search result in duplicate. In case of disagree-
ment, consensus was reached through discussion. The title and
abstract were reviewed during the first stage, after which the
remaining articles were reviewed in depth during the second
stage. Reference lists of potentially valid studies and review
articles were checked to ensure no relevant studies were
missed. Abstracts from meetings were not considered.
Studies were included if they fulfilled the following crite-
ria: (1) the study included adult patients with severe AS quan-
tified by at least an aortic valve area of less than 1.0 cm2 or an
indexed aortic valve area less than 0.6 cm2/m2, a jet velocity
of more than 4.0 m/s, or a mean gradient of more than 40 mm
Hg; (2) patients were considered to be asymptomatic if re-
ported as such, which was left to the discretion of the physi-
cians and investigators of the individual studies and perfor-
mance of exercise testing was not considered mandatory to
confirm absence of symptoms; and (3) at least the event of
death during follow-up and the mean/median duration of fol-
low-up was reported. Studies with a combined inclusion of pa-
tients with moderate and severe AS were excluded unless re-
sults were separately reported for patients with severe AS. In
case there was overlap in the patient populations in different
studies from the same center, we included only the study with
the longest follow-up or largest patient cohort. A list of ex-
cluded articles is available on request.
Data Extraction
Two investigators (S.J.H. and M.Ç.) independently extracted
and crosschecked clinically relevant data and data necessary
for study inclusion and meta-analysis (eAppendix 1 in the
Supplement). Inconsistencies were resolved by discussion.
End Points
For the meta-analysis on the natural history, the primary end
point was all-cause death. Secondary end points consisted of
cardiac death, sudden death, death due to congestive heart
failure, the development of an indication for aortic valve in-
tervention, the development of symptoms, and aortic valve
intervention by either SAVR or transcatheter aortic valve re-
placement. For the meta-analysis of early intervention vs con-
servative treatment, the primary end point was all-cause death.
For the meta-analysis of predictors, the primary end point
consisted of the composite of all-cause death and aortic valve
intervention (or development of symptoms) but allowing for
studies to include hospitalization or congestive heart failure as
additional end point in the composite.
Statistical Analyses
We calculated the log rate of events per 100 patients per year
of observation time and the corresponding standard error
within studies and then used a DerSimonian and Laird random-
effects model to derive pooled estimates and corresponding
limits of the 95% CI10 and back-transformed pooled esti-
mates and limits of the 95% CI to rates per 100 patient-years
Key Points
Question What is the natural history of asymptomatic severe
aortic stenosis, which variables predict prognosis, and can early
intervention improve outcomes?
Findings In this systematic review and meta-analysis of 29 studies
with 4075 patients with 11 901 years of follow-up, the rate of
all-cause death was 5 per 100 conservatively treated patients per
year, of which 3 and 1 were of cardiac and sudden cause,
respectively. Twenty per 100 patients per year developed an
indication for intervention; early intervention was significantly
associated with improved survival.
Meaning Patients with asymptomatic severe aortic stenosis may
develop indication for intervention and have deaths that are
mostly cardiac but not only sudden.
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throughout. If the total amount of follow-up time was not re-
ported, this was calculated by multiplying the number of pa-
tients by the mean follow-up time. In case of 0 events, we de-
rived the upper end of the 95% CI of the rate as described by
Hanley and Lippman-Hand, adding a continuity correction of
0.01 to the numerator, and a continuity correction of 0.01 mul-
tiplied by the mean follow-up time to the denominator to de-
rive rates.11 We explored heterogeneity across studies using the
DerSimonian and Laird between-study variance τ2 statistic12
and calculated 95% prediction intervals for the pooled rates
in addition to conventional CIs taking into account the be-
tween-study variance to reflect residual uncertainty.13 Our
analysis on the natural history consisted of pooling the stud-
ies that reported events occurring only during a period of time
in which patients were asymptomatic and no aortic valve in-
tervention took place. Prespecified subgroup analyses were re-
stricted to the 26 studies with follow-up until aortic valve in-
tervention, investigating heterogeneity by study design
(prospective vs retrospective), year of initiation of patient re-
cruitment (before 1999 vs 1999 or later), number of patients
included in the study (<100 vs ≥100 patients), length of mean
follow-up time (<2 vs ≥2 years), length of accumulated fol-
low-up patient-time (<200 vs ≥200 patient-years), and whether
or not good LV ejection fraction (defined as ≥50%, ≥55%, or
normal) was an inclusion criterion of the study. Subgroup
analyses were accompanied by a test for interaction from ran-
dom-effects meta-regression.
For the comparison of all-cause mortality following early
intervention vs conservative treatment, we included studies
that did not censor patients at the time of intervention and
evaluated long-term mortality. We pooled studies using the
study-level hazard ratios (HRs) in a random-effects model with
Knapp-Hartung modification of the variance as the number of
cohort studies that reported HRs for this comparison was low.
For the pooling of the effect of prognostic indicators on
events, whenever 2 or more studies reported the HRs of the
association between prognostic indicators and events during
follow-up, we pooled them across studies using a random-
effects bayesian meta-analysis. Details are provided in eAp-
pendix 2 in the Supplement. Analyses were performed in Stata
version 14.2 (StataCorp) and WinBUGS version 14 (Medical Re-
search Council Biostatistics Unit).
Results
Study Inclusion
The literature search yielded 2370 studies that were poten-
tially relevant for inclusion in the meta-analysis, and 29 stud-
ies were included in the meta-analysis on the natural history
(eFigure in the Supplement). All studies were observational.
A total of 4075 patients with a median (interquartile range
[IQR]) follow-up of 2.3 (1.6-3.3) years were included in the natu-
ral history analysis (Table 1). In addition, 9 studies were in-
cluded in the meta-analysis comparing an early surgical treat-
ment strategy with watchful waiting, of which 1 was a
randomized clinical trial (eFigure in the Supplement). A total
of 3904 patients with a median (IQR) follow-up of 5.0 (3.7-
5.7) years were included in our analyses comparing an early
surgical treatment strategy with watchful waiting (Table 1).
Meta-analysis on Natural History
The rate of all-cause death was 4.8 (95% CI, 3.6-6.4) per 100
patients per year in 21 studies with 3041 patients with a me-
dian (IQR) follow-up of 2.3 (1.7-3.4) years (Figure 1A). Cardiac
death occurred at a rate of 3.0 (95% CI, 2.2-4.1) per 100
patients per year in 18 studies with 2813 patients with a
median (IQR) follow-up of 2.1 (1.4-2.9) years (Figure 1B). The
rate of death due to congestive heart failure was 2.0 (95% CI,
1.3-3.1) per 100 patients per year in 11 studies with 1809
patients with a median (IQR) follow-up of 2.3 (1.9-2.9) years
(Figure 1C). Sudden death occurred at a rate of 1.1 (95% CI,
0.6-2.1) per 100 patients per year in 12 studies with 1767
patients with a median (IQR) follow-up of 2.3 (1.7-3.1) years
(Figure 1D).
Progression to Aortic Valve Intervention
An indication for aortic valve intervention was reported in 11
studies with 1754 patients with a median (IQR) follow-up of
2.3 (1.8-3.2) years and occurred in 18.1 (95% CI, 12.8-25.4) per
100 patients per year (Figure 2A). There were 16 studies with
2234 patients and median (IQR) follow-up of 1.9 (1.3-3.1) years
that reported the number of patients that developed symp-
toms, with a pooled rate of 18.5 (95% CI, 13.4-25.5) per 100 pa-
tients per year (Figure 2B). Aortic valve intervention was per-
formed in 19.2 (95% CI, 15.5-23.8) per 100 patients per year (21
studies with 3494 patients with a median [IQR] follow-up of
2.3 [1.7-3.0] years) (Figure 2C).
Subgroup Analyses
eTable 1 in the Supplement shows results of subgroup analy-
ses. Studies with shorter total follow-up were associated with
higher rates of all-cause death. Studies with shorter mean and
total follow-up were associated with higher rates of symptom
development and aortic valve interventions. Rates of an indi-
cation for aortic valve intervention (21.0 [95% CI, 15.8-28.0]
vs 10.6 [95% CI, 9.6-11.6] per 100 patients per year; P = .02)
and development of symptoms (21.2 [95% CI, 16.2-27.6] vs
8.7 [95% CI, 7.9-9.7] per 100 patients per year; P = .007) were
markedly higher in prospective vs retrospective studies.
There were no interactions with subgroups by LV ejection
fraction.
Adverse Events
Fifteen studies performed a multivariable analysis on the com-
posite of death or aortic valve intervention. Outcomes were
largely associated with measurements of the severity of AS and
LV dysfunction, with clinical factors being limited to athero-
sclerotic risk factors (eTable 2 in the Supplement). There was
inconsistency in how variables and cutoffs were used in mul-
tivariable models, but pooling consistent variables with 2 or
more results in multivariable analyses resulted in a set of in-
dependent variables (Table 2). Heterogeneity was low for all
pooled analyses. Results were consistent in sensitivity analy-
ses using different assumptions for the prior distribution of τ
(eTable 3 in the Supplement).
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Figure 2. Meta-analysis of Studies on Progression to Aortic Valve Intervention
Indication for aortic valve interventionA
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Indication for intervention rate per 100 patients per y
20 3010
Overall: τ2 = 0.31; 95% PI, 4.9-66.9
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Rosenhek et al,34 2010
Cioffi et al,33 2011
Lancellotti et al,30 2012
Saito et al,29 2012
Levy et al,26 2014
Nagata et al,23 2015
Nishimura et al,19 2016


























0 60 70 8040 50
Symptom development rate per 100 patients per y
20 3010
Development of symptomsB
Source Patients, No./total No. Rate (95% CI)
Rosenhek et al,42 2000
Amato et al,6 2001
Pellikka et al,40 2005
Avakian et al,38 2008
Hristova-Antova et al,35 2009
Rosenhek et al,34 2010
Cioffi et al,33 2011
Lancellotti et al,30 2012
Saito et al,29 2012
Yingchoncharoen et al,28 2012
Zuern et al,25 2014
Nagata et al,23 2015
Nishimura et al,19 2016
Todaro et al,22 2016






























Zilberszac et al,18 2017 76/167 45.6 (36.5-57.1)
Christensen et al,17 2017 22/90 24.3 (16.0-36.9)
Aortic valve interventionC
0 60 70 8040 50
Aortic valve intervention rate per 100 patients per y
20 3010
Source Patients, No./total No. Rate (95% CI)
Overall: τ2 = 0.22; 95% PI, 7.0-52.5
Rosenhek et al,42 2000
Pellikka et al,40 2005
Weisenberg et al,37 2008
Hristova-Antova et al,35 2009
Lafitte et al,36 009
Rosenhek et al,34 2010
Cioffi et al,33 2011
Lancellotti et al,30 2012
Saito et al,29 2012
Yingchoncharoen et al,28 2012
Cho et al,27 2013
Jander et al,24 2014
Levy et al,26 2014
Zuern et al,25 2014
Nagata et al,23 2015
Maréchaux et al,20 2016
Nishimura et al,19 2016






































Zilberszac et al,18 2017 71/167 42.6 (33.8-53.8)
Christensen et al,17 2017 22/90 24.3 (16.0-36.9)
González Gómez et al,16 2017 153/755 20.3 (17.3-23.7)
PI indicates prediction interval.
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Meta-analysis on the Association of Early Intervention
With Outcomes
There were 9 studies that compared patients who underwent
early intervention vs an initial conservative treatment strat-
egy, which included a combined 3904 patients with a
median (IQR) follow-up of 5.0 (3.7-5.7) years (eTable 4 in the
Supplement).5,39,43,47-49 All but 1 randomized clinical trial
used either propensity-score matching or multivariable
models to adjust for differences in baseline characteristics
between treatment groups. Intervention consisted of surgery
in most cases. Our meta-analysis indicates that intervention
was associated with a significant reduction in all-cause mor-
tality during follow-up (HR, 0.38; 95% CI, 0.25-0.58), with
moderate heterogeneity (τ2 = 0.21) (Figure 3).
Discussion
In this systematic review and meta-analysis of 29 studies on
the natural history of patients with asymptomatic severe AS,
we found that there were overall 5 deaths per 100 patients per
year during a conservative treatment strategy, with a high
rate of progressing to a symptomatic state and developing
an indication for aortic valve intervention. Particularly
patients with more severe AS, abnormal LV characteristics,
and atherosclerotic clinical factors were at a higher risk of
death or an indication for intervention. Moreover, among
another 9 studies that investigated performing early inter-
vention, consisting of surgery in the majority of cases
within these studies, early intervention was associated with
a significant reduction in all-cause death during follow-up.
While it has been argued that many patients do not develop
an indication for intervention and that the risk of death is
low during conservative treatment, the results of the cur-
rent meta-analysis suggest otherwise. Indeed, most studies
focus on sudden death, but this meta-analysis demonstrates
that sudden death accounts for only part of cardiac deaths
that occur in asymptomatic patients with severe AS and that
the risk of death may therefore be underestimated. These
data suggest that early intervention may need to be consid-
ered in a greater proportion of patients with asymptomatic
severe AS.
Table 2. Factors Associated With Death or Aortic Valve Intervention
Characteristic HR (95% CrI) τ2 (95% CrI) Source
Peak pressure gradient, per 10 mm Hg 1.22 (1.03-1.44) 0.002 (0-0.067) Yingchoncharoen et al, 201228; Cioffi et al, 201133
Peak aortic jet velocity ≥4.0 m/s 1.93 (1.17-3.18) 0.006 (0-0.131) Nishimura et al, 201619; Saito et al, 201229
Aortic valve area ≤0.6 cm2 1.68 (1.13-2.53) 0.010 (0-0.146) Maréchaux et al, 201620; Rosenhek et al, 201034
Aortic valve calcification ≥ grade 3 2.65 (1.71-4.25) 0.006 (0-0.115) Yingchoncharoen et al, 201228; Nishimura et al, 201619;
Rosenhek et al, 200042
Female 0.97 (0.72-1.33) 0.006 (0-0.113) Rosenhek et al, 201034; Rosenhek et al, 200042
Hypertension 0.66 (0.48-0.93) 0.005 (0-0.089) Zilberszac et al, 201718; Rosenhek et al, 201021;
Rosenhek et al, 200042
Dyslipidemia 1.45 (1.09-1.93) 0.006 (0-0.097) Zilberszac et al, 201718; Nishimura et al, 201619;
Rosenhek et al, 201034; Rosenhek et al, 200042
Diabetes 1.64 (1.09-2.41) 0.044 (0-0.272) Cioffi et al, 201133; Zilberszac et al, 201718;
Rosenhek et al, 201034; Rosenhek et al, 200042
Coronary artery disease 1.32 (0.90-1.91) 0.012 (0-0.161) Zilberszac et al, 201718; Rosenhek et al, 201034;
Rosenhek et al, 200042
Global longitudinal strain on speckle 1.12 (1.02-1.28) 0.002 (0-0.049) Yingchoncharoen et al, 201228; Todaro et al, 201622;
Lancellotti et al, 201230
Valvulo-arterial impedance 1.35 (1.03-1.76) 0.005 (0-0.100) Yingchoncharoen et al, 201228; Todaro et al, 201622
Left ventricular mass Index, per 10 units 1.1 (0.87-1.39) 0.004 (0-0.089) Nagata et al, 201523; Cioffi et al, 201133
Abbreviations: CrI, credible interval; HR, hazard ratio.
Figure 3. Meta-analysis on All-Cause Mortality of Surgery vs an Initial Conservative Treatment Strategy
Hazard ratio
(95% CI) P ValueSource
Overall: τ2 = 0.21
0.01 1010.1
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Currently, the largest and only available randomized clini-
cal trial on asymptomatic patients with severe AS analyzed 145
patients and found that initial surgery vs an initial conserva-
tive treatment significantly reduced the all-cause death and op-
erative or cardiovascular death, even when 74% of patients in
the conservative group required SAVR during follow-up.43 This
study is pivotal in the debate on treating asymptomatic pa-
tients, but it only provides a perspective on patients with very
severe AS, applying inclusion criteria of an aortic valve area of
0.75 cm2 or less with either a jet velocity of 4.5 m/s or more or
a mean gradient of 50 mm Hg or more, while lacking evidence
on the much broader patient population with asymptomatic AS.
Further data from observational studies as summarized in the
current meta-analysis provide these additional insights. The
largest available observational study analyzed 291 propensity-
matched pairs and found that early surgery vs an initial con-
servative treatment significantly reduced the 5-year rates of all-
cause death and hospitalization for heart failure, even when 41%
of patients in the conservative group required SAVR during
follow-up.5 When pooling multiple studies on the effect of in-
tervention on survival, we found that intervention vs conser-
vative treatment was associated with significantly improved
survival with an HR of 0.38. While this may be a true effect,
considering the high rates of death and progression to an indi-
cation for aortic valve intervention (eg, symptoms or LV
dysfunction) among conservatively treated patients in this
meta-analysis, most of the observational studies may be bi-
ased because physicians could have opted for a conservative
treatment strategy for patients owing to a high risk for surgery,
as was often the case before the introduction of transcatheter
aortic valve replacement, when most of these studies were
performed.50 Moreover, not all studies specifically evaluated the
effect of intervention within a short (eg, 3 months) period after
the diagnosis of severe AS. Patients who went on to have inter-
vention at a later follow-up time are inherently a selected group
with a better prognosis because the highest-risk patients may
have died within the early follow-up period. Indeed, Le Tour-
neau and coauthors39 found that the point estimate of the HR
in favor of surgery was much larger if conservative treatment
was compared with surgery being performed within 1 year of
presentation as opposed to surgery at any time during fol-
low-up (HR, 0.58 vs HR, 0.39). Data from the RECOVERY trial
are consistent with that of these observational studies,43 but
additional results from ongoing randomized clinical trials
comparing an early interventional treatment strategy and a
conservative strategy in asymptomatic patients with severe AS
will add significant knowledge and provide important insight
to substantiate the role of early intervention (eTable 5 in the
Supplement).
The decision to undergo early intervention should de-
pend on a critical assessment of symptoms and careful and
individualized consideration of potential benefits and harms.
Cardiac magnetic resonance to detect LV damage further-
more helps identify patients that may benefit from early
intervention.51 Apart from LV dysfunction as an indication to
perform SAVR in patients with asymptomatic severe AS, cur-
rent clinical guidelines provide several additional recommen-
dations to consider intervention in patients with asymptom-
atic severe AS.1 Our meta-analysis of variables associated with
mortality-related outcomes indicates that prognosis is signifi-
cantly worse if global longitudinal strain or valvulo-arterial im-
pedance is present even with a preserved LV function,22,23,28,33
if AS is more severe as measured by higher valve gradient and
lower valve area, and if atherosclerotic risk factors, such as dys-
lipidemia or diabetes, are present. These additional diseases
and comorbid characteristics are not considered in current
guidelines or are inconsistently recognized in North Ameri-
can and European guidelines. Therefore, we suggest that car-
diologists and surgeons take these additional factors into ac-
count when deciding to perform early intervention or initiate
a conservative treatment strategy. Of note, our subgroup analy-
sis could not confirm that lower LV ejection fraction was as-
sociated with worse outcomes, which is most likely related to
the criteria used in the individual articles; almost all studies
included patients with preserved LV ejection fraction.
Strengths and Limitations
An important strength is that a large number of studies could
be pooled in a random-effects model with moderate statisti-
cal heterogeneity, increasing the validity of the results. The in-
cluded studies consisted exclusively of patients with asymp-
tomatic severe AS, unlike many other studies and reviews that
have not stratified results according to the severity of AS in
asymptomatic patients.7,52 Lastly, using bayesian methods for
meta-analyses of a low number of studies allowed a more re-
liable estimation of between-trial variance and its uncer-
tainty to identify particular disease and patient factors that
affect the prognosis of asymptomatic severe AS. This re-
sulted in identifying several variables that are currently not in-
cluded in clinical guidelines.
This is a meta-analysis of observational studies, which is
dependent on the quality of the individual studies that were
included. Many of the studies were single center and retro-
spective, and it may therefore have been difficult to adjudi-
cate events related to the development of symptoms and in-
dications for intervention during follow-up. Second, only a few
studies routinely performed stress testing in patients with
asymptomatic severe AS, and we were therefore not able to de-
termine whether all patients in these studies were truly asymp-
tomatic. In addition, studies mainly reported that patients with
severe AS referred to their clinic were included but did not
clarify whether patients already had severe AS a certain time
before primarily being evaluated in the clinic (eg, prevalent
cases) or had mild or moderate AS when primarily being evalu-
ated and progressed to severe AS just before a later check
(eg, incident cases). Nevertheless, there was considerable
heterogeneity in our meta-analyses of event rates. Although
subgroup analyses to detect heterogeneity within meta-
analyses of observational studies should be interpreted with
caution, our subgroup analyses revealed that the type of study
(prospective vs retrospective) and the duration of follow-up
(short vs long mean and total follow-up time) were associ-
ated with differences in event rates. This may have been the
result of more closely monitoring patients who were prospec-
tively followed, with earlier recognition of symptoms and
timely referral for intervention, as opposed to a less strict fol-
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low-up regimen in retrospective studies. Moreover, the
higher rates of symptom development, (an indication for)
aortic valve intervention, all-cause death, and sudden death
in studies with a shorter mean and total length of follow-up
of a conservative strategy are most likely related to shorter
follow-up due to the occurrence of these events, and publi-
cation bias may also play a role. Lastly, the effect of the
associations between variables from multivariable analysis
of several studies could not be pooled due to different defi-
nitions or cutoffs used in the models. Initiatives like the
Valve Academic Research Consortium can further standard-
ize studies to improve meta-analyses.53
Conclusions
In this meta-analysis, asymptomatic severe AS was associ-
ated with a high rate of developing an indication for aortic valve
intervention, while all-cause, cardiac, and sudden death
occurred in 4.8, 3.0, and 1.1, respectively, of 100 patients per
year during a conservative strategy. Therefore, it is impor-
tant to consider not only sudden death but also cardiac
death due to heart failure or other causes. Patients with
higher severity of AS, low-flow AS, evidence of LV damage,
and atherosclerotic risk factors are at particular high risk
of death or requiring intervention. Moreover, our meta-
analysis suggested that surgery vs an initial conservative
treatment strategy is associated with better long-term sur-
vival. Although existing guidelines provide some guidance
on when to perform SAVR in patients with asymptomatic
severe AS, this meta-analysis provides additional data to
support a recommendation to consider early intervention in
patients at high risk of adverse events. Further results from
the ongoing randomized clinical trials are required to sub-
stantiate the role of early intervention in patients with
asymptomatic severe AS.
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